The Complete Solution for Total Vein Care
From start to finish, only AngioDynamics provides the full spectrum of products and services physicians need for minimally invasive varicose vein treatment. It’s the kind of complete solution that only a company focused on total vein care can offer.
As the pioneer in endovenous laser treatment, AngioDynamics’ technology and clinical results are unsurpassed. That’s why the complete solution from AngioDynamics is the best solution in total vein care management.
AngioDynamics' solid-state diode laser is reliable and proven technology that makes treating varicose veins easier.
- Enhanced ease of use
- Expanded patient data management
- Superior diode reliability that allows for our industry-leading 3-year warranty
- Fiber Recognition System (FRS) for immediate activation of procedural pre-sets and added safety
- Contact your local sales representative for more information and to inquire about purchasing or leasing options
- Introducing our all new NeverTouch® kits featuring the NeverTouch fiber tip technology and TRE-Sheath® procedure sheath
- One Piece Sheath (OPS) bare-fiber kit features our unique OPS sheath with guidance markings for controlled pullback
- Safety glasses, wires, and access kits
Sotradecol (sodium tetradecyl sulfate injection)
Vein Treatment with Sotradecol (Sodium Tetradecyl Sulfate Injection)
- Available in 1% or 3% Solution
- The commercially only FDA-approved STS injection available in the U.S.
Important Safety Information for Sotradecol Injection
Sotradecol is contraindicated in patients with previous hypersensitivity to the drug; inflammation or incompetence of superficial or deep veins; phlebitis migrans; acute cellulitis; allergic conditions; acute infections; varicosities caused by abdominal and pelvic tumors unless the tumor has been removed; bedridden patients; diabetes; toxic hyperthyroidism; tuberculosis; asthma; neoplasm; sepsis; blood dyscrasias; and acute respiratory or skin diseases.
Due to the risk of deep vein thrombosis, patients should be evaluated for valvular competency and deep venous patency before treatment and slow injections of a small volume (< 2 mL) should be injected. Patients should be monitored post-treatment for deep vein thrombosis and pulmonary embolism. Extreme caution must be exercised in the presence of underlying arterial disease.
Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and use the smallest effective volume at each injection site.
Allergic reactions, including fatal anaphylaxis, have been reported. As a precaution, it is recommended that 0.5 mL of Sotradecol be injected, followed by observation for several hours before administration of a second or larger dose. Emergency resuscitation equipment should be immediately available, and the physician prepared to treat an anaphylactic reaction.
At least 6 deaths have been reported. Four of the deaths were cases of anaphylaxis; one in a patient with a history of asthma, a contraindication to Sotradecol use. Another death was in a patient who was taking an antiovulatory agent. One death (pulmonary embolism) occurred in a patient not taking an antiovulatory agent, treated with sodium tetradecyl acetate. Other adverse reactions reported include pulmonary embolism; local injection site reactions (pain, urticaria, ulceration); permanent discoloration of sclerosed vein segment; sloughing and necrosis of tissue following extravasation of the drug; allergic reactions (hives, asthma, hayfever); headache; nausea; and vomiting.